Kiora Pharmaceuticals (KPRX) Income from Discontinued Operations (2022 - 2024)

Kiora Pharmaceuticals (KPRX) has reported Income from Discontinued Operations for 3 consecutive years, with -$4.2 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Income from Discontinued Operations fell 86.17% year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2024 stood at -$16.2 million (changed 0.12% YoY), and the FY2024 full-year result was $3.6 million, up 127.56% from the prior year.
• Income from Discontinued Operations fell to -$4.2 million in Q4 2024 per KPRX's latest filing, from -$3.4 million in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at -$2.3 million in Q4 2023 and bottomed at -$6.3 million in Q3 2023.
• Historically, Income from Discontinued Operations has averaged -$4.0 million across 3 years, with a median of -$3.8 million in 2024.
• The widest YoY moves for Income from Discontinued Operations: up 45.77% in 2024, down 86.17% in 2024.
• Over 3 years, Income from Discontinued Operations stood at -$2.5 million in 2022, then gained by 9.2% to -$2.3 million in 2023, then tumbled by 86.17% to -$4.2 million in 2024.
• According to Business Quant data, Income from Discontinued Operations over the past three periods registered -$4.2 million, -$3.4 million, and -$2.3 million for Q4 2024, Q3 2024, and Q4 2023 respectively.